# Celldex Therapeutics share price today (Celldex Therapeutics, Inc., CLDX)

> Celldex Therapeutics, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. CLDX · Healthcare · Biotechnology · data as of 5 November 2026. Page: https://www.sectoralpha.in/us/stocks/cldx

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: $28.27 (+23.4% in a year)
- Revenue (Jun 2026): ₹0.0 B
- Profit (Jun 2026), incl. one-off: −₹0.1 B (one-off item, see below)
- ROE: −49%, FY25

Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. ## What is the Celldex Therapeutics share price today? Celldex Therapeutics, Inc.'s share price was $28.27 at the close on 5 November 2026. It has been moving sideways for 7 weeks. That is 13.6% below its average price over the last 200 trading days. In the last 52 weeks it traded between $23 and $42, and at that close it sat 28% of the way up from that low. Over the past 13 weeks it has done worse than the S&P 500, and it has been behind for 7 weeks running. Over the last 10 years the share price moved −59% while the S&P 500 moved +245%, so it is behind the index over that whole period. It was last ahead over 13 weeks in the week of 18 September 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Celldex Therapeutics pay? Celldex Therapeutics, Inc. pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is Celldex Therapeutics on? Celldex Therapeutics is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is Celldex Therapeutics profitable? Celldex Therapeutics, Inc. posted a net loss of ₹0.1 B in the Jun 2026 quarter. That quarter includes a one-off gain bigger than its revenue, so the comparison with last year does not reflect normal business. The full FY25 year was a loss of ₹0.3 B. That loss is 3,34,104.5% of the quarter's revenue. The same quarter a year earlier lost ₹0.1 B. 12 of the last 12 reported quarters were loss-making. Read this profit with care: at −₹0.1 B it is bigger than the quarter's whole revenue of ₹0.0 B. No business earns more than it takes in from sales, so this is a one-off item (for example a debt settlement, a tax write-back or an asset sale), not money the business earned. The underlying business is running at a −3,66,468.2% operating margin. The jump on last year, and any P/E built on this profit, come from the one-off, not from a real turn in earnings. This company reports in its home currency, not US dollars, so the money charts are left out here. The figures in the text are in that currency (₹); nothing is converted. ## How much revenue does Celldex Therapeutics make, and is it growing? Celldex Therapeutics, Inc. reported ₹0.0 B of revenue in the Jun 2026 quarter, −97.0% on the same quarter a year earlier. Over 4 years it has grown −24.1% a year on average. The last full year, FY25, came in at ₹0.0 B. FY25 revenue was ₹0.0 B, −78.0% on the year before. Recent pace: the last four quarters grew −88.8% on average, against −24.1% a year over the longer run, so this year is growing slower than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew −88.3%, against −61.8% a year over the last 8 quarters (rolling over). This company reports in its home currency, not US dollars, so the money charts are left out here. The figures in the text are in that currency (₹); nothing is converted. ## How much of its sales does Celldex Therapeutics keep? Celldex Therapeutics, Inc.'s sales have fallen to very little: FY25 revenue was ₹0.0 B, against ₹0.0 B in FY24. On sales that small an operating margin is not a useful reading, so this section is left out until sales recover. ## Is Celldex Therapeutics' profit turning into cash? Celldex Therapeutics, Inc.'s cash-flow history is too short to judge how much of its profit turns into cash. In FY25 its operations used ₹0.2 B of cash, against −₹0.3 B of profit. After ₹0.0 B of spending on assets, free cash was −₹0.2 B: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. What to look at next: it spends almost nothing on new assets, so the cash goes on running the business. The next section shows the spending figures. This company reports in its home currency, not US dollars, so the money charts are left out here. The figures in the text are in that currency (₹); nothing is converted. ## Where does Celldex Therapeutics' cash go? Celldex Therapeutics, Inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent ₹0.0 B on assets over the last 3 years. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: ₹0.0 B over the last 3 years. In short: almost nothing is being spent on new assets, so the cash goes on running the business. This company reports in its home currency, not US dollars, so the money charts are left out here. The figures in the text are in that currency (₹); nothing is converted. ## What is Celldex Therapeutics' P/E ratio, and how does it compare with its own history? Celldex Therapeutics, Inc. has no P/E right now, because its earnings are negative. The revenue and margin sections are where a turn would show first. The P/E comes back here once profit turns positive. ## Is the Celldex Therapeutics business getting better or worse? Celldex Therapeutics, Inc.'s business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 12 quarters of 2 measures, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. The latest quarter’s profit includes a one-off item bigger than the normal business, so the profit line is shown but does not count in this reading. The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does Celldex Therapeutics earn on its capital? Celldex Therapeutics, Inc. earned a ROE of −49% in FY25. Its return on capital used (ROIC) is left out: on sales this small it reads −33%, a number that says nothing useful about the business. ## Does Celldex Therapeutics have too much debt? Celldex Therapeutics, Inc. has total debt of ₹0.0 B against shareholder equity of ₹0.7 B as of Jun 2026, so its debt is 0.01× its equity, which is very little. Year by year, that ratio went from 0.01 in FY21 to 0.00 in FY25. So the returns on this page come from the business, not from borrowed money. This company reports in its home currency, not US dollars, so the money charts are left out here. The figures in the text are in that currency (₹); nothing is converted. ## What is the Celldex Therapeutics shareholding pattern? 13.2% of Celldex Therapeutics, Inc.'s tradable shares are in short positions, which are bets that the price will fall, so a large group of traders is betting against it. At normal trading volumes, closing those positions would take about 4.3 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is Celldex Therapeutics from balance-sheet trouble? For Celldex Therapeutics, Inc., the Z-score is 12.97. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is well clear of danger. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of 12.97 is well clear of the danger zone, so the balance sheet is not the risk here. ## How does Celldex Therapeutics rank in its industry? There is no score against its industry: Celldex Therapeutics, Inc. is not among the largest members shown in this industry comparison for Biotechnology. The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown. ## Which companies is Celldex Therapeutics compared with? No sector comparison is shown here, not among the largest members shown in this industry comparison. ## Which companies are close to Celldex Therapeutics in size? Celldex Therapeutics is the 69th largest of 211 Biotechnology companies on Sector Alpha by market value (scores of 5 November 2026). Just above it: Xencor, Inc., Arcus Biosciences, Inc. and NewAmsterdam Pharma Company N.V. Just below it: Septerna, Inc., Recursion Pharmaceuticals, Inc. and Aurinia Pharmaceuticals Inc. ### Biotechnology companies close in size

1. [Xencor, Inc.](https://www.sectoralpha.in/us/stocks/xncr) $2.6 billion
2. [Arcus Biosciences, Inc.](https://www.sectoralpha.in/us/stocks/rcus) $2.5 billion
3. [NewAmsterdam Pharma Company N.V.](https://www.sectoralpha.in/us/stocks/nams) $2.3 billion
4. Celldex Therapeutics, Inc. $2.2 billion
5. [Septerna, Inc.](https://www.sectoralpha.in/us/stocks/sepn) $2.2 billion
6. [Recursion Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/rxrx) $2.2 billion
7. [Aurinia Pharmaceuticals Inc.](https://www.sectoralpha.in/us/stocks/auph) $2.2 billion

[All 211 Biotechnology companies, largest first](https://www.sectoralpha.in/us/sectors/biotechnology#all-companies)

### Companies close in size in other industries

1. [Northern Oil and Gas, Inc.](https://www.sectoralpha.in/us/stocks/nog) $2.4 billion · Oil & Gas Exploration & Production
2. [Ducommun Incorporated](https://www.sectoralpha.in/us/stocks/dco) $2.4 billion · Aerospace & Defense
3. Celldex Therapeutics, Inc. $2.4 billion
4. [NETSTREIT Corp.](https://www.sectoralpha.in/us/stocks/ntst) $2.3 billion · REIT - Retail
5. [ADMA Biologics, Inc.](https://www.sectoralpha.in/us/stocks/adma) $2.3 billion · Biotechnology

## What else do people ask about Celldex Therapeutics? ### What were Celldex Therapeutics's latest quarterly results? Celldex Therapeutics, Inc. reported revenue of ₹0.0 B and a net loss of ₹0.1 B for the Jun 2026 quarter. The operating margin was −3,66,468.2%, 3,57,720.7 percentage points lower than a year earlier (as of 5 November 2026). ### What is Celldex Therapeutics's market cap? Celldex Therapeutics, Inc.'s market capitalisation is $2.2 B at a stock price of $28.27. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 5 November 2026). ### How is Celldex Therapeutics performing? Celldex Therapeutics, Inc.'s share price has been moving sideways for 7 weeks. Over the past 13 weeks it has done worse than the S&P 500, for 7 weeks running. This describes what the data did, not a rating (as of 5 November 2026). ### Will Celldex Therapeutics's stock price go up? This page does not forecast Celldex Therapeutics, Inc.'s stock price. What it shows instead: the stock price is $28.27, and it has been moving sideways for 7 weeks. Nobody can reliably say which way a price will move, and this site does not try (as of 5 November 2026). ### Does Celldex Therapeutics have too much debt? No, Celldex Therapeutics, Inc. has little debt: its debt is 0.02× its equity. A year-by-year history of its borrowings is not in our data, so this uses the latest reading. So the returns on this page come from the business, not borrowed money (as of 5 November 2026). ### What could break the Celldex Therapeutics story? Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 5 November 2026). ### Is Celldex Therapeutics a stock worth studying right now? What the numbers show: Celldex Therapeutics, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 5 November 2026). This is research, not advice. We’re not SEBI-registered.